- Home
- CCD vs FLGT Comparison
CCD vs FLGT Comparison
Compare CCD & FLGT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCD
- FLGT
- Stock Information
- Founded
- CCD 2014
- FLGT 2011
- Country
- CCD United States
- FLGT United States
- Employees
- CCD N/A
- FLGT N/A
- Industry
- CCD Trusts Except Educational Religious and Charitable
- FLGT Medical Specialities
- Sector
- CCD Finance
- FLGT Health Care
- Exchange
- CCD Nasdaq
- FLGT Nasdaq
- Market Cap
- CCD 555.7M
- FLGT 587.3M
- IPO Year
- CCD N/A
- FLGT 2016
- Fundamental
- Price
- CCD $20.81
- FLGT $21.95
- Analyst Decision
- CCD
- FLGT Buy
- Analyst Count
- CCD 0
- FLGT 3
- Target Price
- CCD N/A
- FLGT $25.33
- AVG Volume (30 Days)
- CCD 96.1K
- FLGT 209.4K
- Earning Date
- CCD 01-01-0001
- FLGT 08-01-2025
- Dividend Yield
- CCD 10.61%
- FLGT N/A
- EPS Growth
- CCD N/A
- FLGT N/A
- EPS
- CCD N/A
- FLGT N/A
- Revenue
- CCD N/A
- FLGT $303,223,000.00
- Revenue This Year
- CCD N/A
- FLGT $15.19
- Revenue Next Year
- CCD N/A
- FLGT $10.58
- P/E Ratio
- CCD N/A
- FLGT N/A
- Revenue Growth
- CCD N/A
- FLGT 4.31
- 52 Week Low
- CCD $16.93
- FLGT $14.57
- 52 Week High
- CCD $24.68
- FLGT $23.56
- Technical
- Relative Strength Index (RSI)
- CCD 63.79
- FLGT 62.67
- Support Level
- CCD $20.37
- FLGT $21.47
- Resistance Level
- CCD $20.59
- FLGT $22.61
- Average True Range (ATR)
- CCD 0.20
- FLGT 0.55
- MACD
- CCD 0.05
- FLGT -0.03
- Stochastic Oscillator
- CCD 88.88
- FLGT 65.26
About CCD Calamos Dynamic Convertible & Income Fund
Calamos Dynamic Convertible and Income Fund operates as a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income and capital appreciation. It predominantly invests in a portfolio of convertible securities, investment grade and below investment grade bonds, loans, equity-linked notes, and floating rate securities.
About FLGT Fulgent Genetics Inc.
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.